Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).
作者信息
Gentile Ivan, Giaccone Agnese, Scirocco Maria Michela, Di Brizzi Francesco, Cuccurullo Federica, Silvitelli Maria, Ametrano Luigi, Alfè Francesco Antimo, Pietroluongo Daria, Irace Irene, Chiariello Mariarosaria, De Felice Noemi, Severino Simone, Viceconte Giulio, Moriello Nicola Schiano, Maraolo Alberto Enrico, Buonomo Antonio Riccardo, Scotto Riccardo
机构信息
Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy.
Department of Infectious Diseases, Unit of Geriatric Infectious Diseases, AORN Ospedali Dei Colli, Cotugno Hospital, Naples, Italy.
出版信息
BMC Infect Dis. 2025 Apr 29;25(1):633. doi: 10.1186/s12879-025-11043-w.
Abstract
摘要
相似文献
1
Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).更正：奈玛特韦/利托那韦降低新型冠状病毒感染患者严重结局风险的疗效：一项真实世界完全匹配病例对照研究（SAVALO研究）
BMC Infect Dis. 2025 Apr 29;25(1):633. doi: 10.1186/s12879-025-11043-w.
2
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).奈玛特韦/利托那韦降低新冠病毒感染患者严重后果风险的疗效：一项真实世界完全匹配病例对照研究（SAVALO研究）
BMC Infect Dis. 2024 Dec 18;24(1):1434. doi: 10.1186/s12879-024-10303-5.
3
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
4
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦/利托那韦片用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
5
Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.美国科罗拉多州奥密克戎变异株（包括 BA.4 和 BA.5）流行期间门诊 COVID-19 患者使用奈玛特韦-利托那韦的真实世界数据：一项回顾性队列研究。
Lancet Infect Dis. 2023 Jun;23(6):696-705. doi: 10.1016/S1473-3099(23)00011-7. Epub 2023 Feb 10.
6
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.奥密克戎变异株流行期间香港社区居住、活动的经实验室确诊的 2 型严重急性呼吸综合征冠状病毒 2 感染患者中莫努匹韦和奈玛特韦/利托那韦对比死亡率、住院率和住院结局的真实世界疗效：一项观察性研究。
Lancet. 2022 Oct 8;400(10359):1213-1222. doi: 10.1016/S0140-6736(22)01586-0.
7
Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.奥密克戎 BA.2 波期间香港住院的 COVID-19 患者无入院时吸氧需求的患者中早期莫努匹韦或奈玛特韦-利托那韦的真实世界疗效：一项回顾性队列研究。
Lancet Infect Dis. 2022 Dec;22(12):1681-1693. doi: 10.1016/S1473-3099(22)00507-2. Epub 2022 Aug 24.
8
Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant.在比利时奥密克戎变异株背景下，奈玛特韦-利托那韦作为治疗新冠病毒感染的真实世界成本效益分析
Front Public Health. 2025 Feb 3;12:1432821. doi: 10.3389/fpubh.2024.1432821. eCollection 2024.
9
Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study.奈玛特韦/利托那韦在 COVID-19 重症住院患者和有进展为重症风险患者中的疗效和安全性：一项真实世界研究。
J Intensive Care Med. 2024 Aug;39(8):742-750. doi: 10.1177/08850666241228841. Epub 2024 Feb 14.
10
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.奥密克戎变异株流行期间，未住院的 2 型糖尿病合并 SARS-CoV-2 感染患者接受莫努匹韦或奈玛特韦/利托那韦治疗后的全因住院和死亡分析。
JAMA Netw Open. 2023 May 1;6(5):e2314393. doi: 10.1001/jamanetworkopen.2023.14393.
本文引用的文献
1
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).奈玛特韦/利托那韦降低新冠病毒感染患者严重后果风险的疗效：一项真实世界完全匹配病例对照研究（SAVALO研究）
BMC Infect Dis. 2024 Dec 18;24(1):1434. doi: 10.1186/s12879-024-10303-5.
Zotero 插件